Insights
Search Results
Client Highlights
1.13.26
Wilson Sonsini Advises Proxima on $80 Million Seed Financing
On January 13, 2026, Proxima (formerly VantAI), the AI-native biotech company pioneering the next generation of AI-driven drug discovery for proximity therapeutics, announced an oversubscribed $80 million Seed financing.
Case Studies
12.11.25
How Wilson Sonsini Helped Ensure Light Horse Therapeutics’ Impressive Debut
Light Horse Therapeutics is pioneering new technologies to tackle the root causes of disabling and life-threatening diseases. Using precision gene editing applied to small-molecule drug discovery, its innovative approach is currently targeting historically challenging cancers, with plans to apply the technology to other therapeutic areas in the future.
Client Highlights
11.26.25
Wilson Sonsini Advises Dayra Therapeutics on Strategic Collaboration with Biogen Inc.
On November 24, 2025, Dayra Therapeutics, a start-up focused on developing oral macrocyclic peptide therapeutics to treat a range of human diseases, announced a research collaboration with Biogen Inc.
News Articles
10.17.25
2026 Lawdragon 500 Leading Dealmakers in America Recognizes Wilson Sonsini Attorneys
On October 17, 2025, Lawdragon published the sixth edition of its Leading Dealmakers in America guide, honoring the lawyers who shake the world with the deals they make happen. The list was compiled through Lawdragon’s time-honed methodology, independent journalistic research, robust and simple submissions from as wide of a group as possible, and vetting from established dealmakers and clients.
Client Highlights
10.17.25
Wilson Sonsini Advises Omeros on Asset Purchase and License Agreement with Novo Nordisk
On October 15, 2025, Novo Nordisk and Omeros Corporation announced that they have entered into a definitive asset purchase and license agreement for the candidate drug zaltenibart (OMS906) in clinical development for rare blood and kidney disorders. Wilson Sonsini Goodrich & Rosati advised Omeros on the transaction.
Client Highlights
7.10.25
Wilson Sonsini Advises Iambic Therapeutics on Technology and Research Collaboration with Revolution Medicines
On July 9, 2025, Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, and Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced a technology and research collaboration to pursue novel drug candidates using Iambic’s leading AI models. Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction.
News Articles
6.05.25
2025 Chambers USA Guide Recognizes Wilson Sonsini Practices, Attorneys
The 2025 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 39 geography-specific practice categories and named 86 Wilson Sonsini attorneys among the best in their fields. This year, the firm received three new practice area rankings, including in the Artificial Intelligence category, and four improved practice area rankings.
Client Highlights
1.13.25
Wilson Sonsini Advises Light Horse Therapeutics on $62 Million Series A
Wilson Sonsini advised Light Horse Therapeutics, a developer of small molecule therapeutics, on its debut $62 million Series A financing. The financing, announced on January 9, 2025, was led by founding investor Versant Ventures and included Mubadala Capital as well as three strategic investors: Bristol-Myers Squibb Co, Taiho Ventures, and AbbVie. Light Horse is the latest company started by Versant’s Inception Discovery Engine, and its scientific co-founders are Brian Liau, Ph.D., Ben Cravatt, Ph.D., and Nathanael Gray, Ph.D.
Client Highlights
1.13.25
Wilson Sonsini Advises Light Horse Therapeutics on Strategic Collaboration with Novartis
Wilson Sonsini advised Light Horse Therapeutics, a developer of small molecule therapeutics, on its multi-target collaboration with Novartis to identify and develop therapeutics using the biotech’s proprietary platform. Under the terms of the agreement, announced on January 9, 2025, Light Horse will receive a $25 million upfront payment. The company is also eligible for $1 billion in further research, development, and sales milestones, in addition to royalties on licensed therapeutics. Further details are undisclosed.
Client Highlights
12.06.24
Wilson Sonsini Advises Dewpoint Therapeutics on Strategic Research Collaboration with MTPC
On December 4, 2024, Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced that it has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC) to advance Dewpoint’s novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS), effective December 1, 2024.
Client Highlights
12.06.24
Wilson Sonsini Advises Saniona on Licensing Agreement with Acadia Pharmaceuticals for SAN711 in Neurological Diseases
On November 26, 2024, Saniona, a clinical-stage biopharmaceutical company, announced a partnership with Acadia Pharmaceuticals (Acadia) for the development and commercialization of SAN711 in neurological diseases. Saniona will receive up to $610 million, including a $28 million upfront payment and up to $582 million in development, regulatory, and commercial milestone payments, along with tiered royalties from mid-single digits to low double digits on global net sales of SAN711. In addition, Acadia will provide financial support for Saniona’s ongoing Phase 1 clinical study and preparation for the Phase 2 clinical study.
News Articles
10.21.24
Firm Attorneys Recognized in 2025 Lawdragon 500 Leading Dealmakers in America Guide
On October 18, 2024, Lawdragon published its fifth edition of its Leading Dealmakers in America guide. The 2025 guide recognizes “the eminents of M&A, the power players of private equity, the consiglieres of capital markets” and “the lawyers firms cherish for their swagger, can-do hustle, and ability to move the needle with clients and firms themselves.”